Publication details
Edoxaban – farmakologický profil
| Title in English | Edoxaban – pharmacological profile |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | edoxaban; direct inhibitor of factor Xa; atrial fibrillation; thromboembolic disease; deep vein thrombosis; pulmonary embolism |
| Description | Edoxaban is a direct inhibitor of factor Xa in the coagulation cascade. It reduces the formation of thrombin, prolongs clotting time and reduces the risk of development of blood clots. Its main therapeutic indication is the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and the presence of one or more risk factors such as congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. The efficacy and safety of edoxaban compared to warfarin was presented in the large clinical trial ENGAGE AF-TIMI 48, and in the ENSURE-AF study involving patients with atrial fibrillation undergoing synchronised electrical cardioversion. Another indication for edoxaban is the treatment of deep vein thrombosis, pulmonary embolism and prevention of recurrent vein thrombosis and pulmonary embolism. The study Hokusai-VTE showed that edoxaban is non-inferior to warfarin in the primary efficacy parameter. Regarding safety, there was a significant reduction of clinically relevant bleeding with edoxaban as compared to warfarin. |